New InsiGHTS Trial of TransCon® hGH (Lonapegsomatropin) in Turner Syndrome Demonstrated Comparable Efficacy and Safety to Daily Somatropin at Week 52

Annualized height velocity of 9.05 cm/year (LS mean) for TransCon hGH-treated children was similar at Week 52 to daily somatropin-treated ...

Ascendis Pharma: New InsiGHTS Trial of TransCon hGH (Lonapegsomatropin) in Turner Syndrome Demonstrated Comparable Efficacy and Safety to Daily Somatropin at Week 52

Annualized height velocity of 9.05 cm/year (LS mean) for TransCon hGH-treated children was similar at Week 52 to daily somatropin-treated children - TransCon hGH showed a safety and tolerability profi ...

Kyntra Bio, Inc. (NASDAQ:KYNB) Q4 2025 Earnings Call Transcript

Kyntra Bio, Inc. (NASDAQ:KYNB) Q4 2025 Earnings Call Transcript March 16, 2026 Kyntra Bio, Inc. beats earnings expectations. Reported EPS is $-3.61, expectations were $-3.885. Operator: Thank you for ...

Kyntra Bio (KYNB) Q4 2025 Earnings Call Transcript

Each forward-looking statement is subject to risks and uncertainties that could cause actual results and events to differ ...